NEWS
LATEST
FULL LIST
-
Co-Axial SWIFT – Embedding Biomimetic Vascular Networks with Co-axial Sacrificial Writing into Functional Tissue Introduction
Introduction Bioprinting human tissues and organs that include biomimetic vascular networks is becoming increasingly essential in the field of regenerative medicine. The major challenge lies in creating perfusable channels within cellular and acellular matrices that mirror the complex structures of native blood vessels. A recent study by Stankey et al., published in Advanced Materials, introduces…
-
WFIRM publishes Science Translation Paper on Full-Thickness Bioprinted Skin
New milestone reached in bioprinting with the successful creation of full-thickness human skin, as detailed in a recent study published in Science Translational Medicine. Researchers from the Wake Forest Institute for Regenerative Medicine (WFIRM) have developed a bioprinted skin graft that mimics the complexity and functionality of natural human skin, offering new hope for improved…
-
Redwire to Test 3D Bioprinted Liver Tissue in Space, Reinforcing the Company’s Focus on Transforming the Future of Organ Transplantation on Earth
JACKSONVILLE, Fla. (July 30, 2024) – Redwire Corporation (NYSE: RDW), a leading innovator in space infrastructure, announced a pioneering experiment set for launch to the International Space Station (ISS). This mission aims to study the effects of microgravity on tissue bioprinting and culturing, in collaboration with the Wake Forest Institute of Regenerative Medicine (WFIRM). Redwire…
-
ARPA-H Launches Groundbreaking Program to Push Further Bioprinting Therapies on Demand
Addressing the Organ Shortage Crisis The Advanced Research Projects Agency for Health (ARPA-H), a part of the U.S. Department of Health and Human Services (HHS), has announced the Personalized Regenerative Immunocompetent Nanotechnology Tissue (PRINT) program. This ambitious initiative aims to help push forward organ transplantation by leveraging cutting-edge bioprinting technology and regenerative medicine to potentially…
-
Aspect Biosystems receives Canadian Government funding to establish biomanufacturing center for bioprinted therapies
Vancouver, BC, Canada – July 10, 2024 – Aspect Biosystems, a biotech company which has chosen to focus on bioprinting tissue therapeutics, has secured a $72.75 million investment from the Canadian and British Columbian governments. This funding is a significant contribution to a $200 million, multi-year initiative aimed at enhancing Aspect’s clinical biomanufacturing capabilities, comprehensive…
Subscribe
Enter your email below to receive updates.
The Business of Biofabrication 